Bristol-Myers Squibb (BMY) Revenue & Revenue Breakdown
Bristol-Myers Squibb Revenue Highlights
Latest Revenue (Y)
$45.01B
Latest Revenue (Q)
$12.20B
Main Segment (Y)
Eliquis
Main Geography (Y)
UNITED STATES
Bristol-Myers Squibb Revenue by Period
Bristol-Myers Squibb Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $45.01B | -2.50% |
| 2022-12-31 | $46.16B | -0.49% |
| 2021-12-31 | $46.38B | 9.09% |
| 2020-12-31 | $42.52B | 62.62% |
| 2019-12-31 | $26.14B | 15.89% |
| 2018-12-31 | $22.56B | 8.59% |
| 2017-12-31 | $20.78B | 6.94% |
| 2016-12-31 | $19.43B | 17.31% |
| 2015-12-31 | $16.56B | 4.29% |
| 2014-12-31 | $15.88B | -3.09% |
| 2013-12-31 | $16.39B | -7.01% |
| 2012-12-31 | $17.62B | -17.05% |
| 2011-12-31 | $21.24B | 9.03% |
| 2010-12-31 | $19.48B | 3.59% |
| 2009-12-31 | $18.81B | -8.69% |
| 2008-12-31 | $20.60B | 6.46% |
| 2007-12-31 | $19.35B | 8.00% |
| 2006-12-31 | $17.91B | -6.73% |
| 2005-12-31 | $19.21B | -0.89% |
| 2004-12-31 | $19.38B | -7.25% |
| 2003-12-31 | $20.89B | 15.32% |
| 2002-12-31 | $18.12B | -6.71% |
| 2001-12-31 | $19.42B | 6.63% |
| 2000-12-31 | $18.22B | -9.92% |
| 1999-12-31 | $20.22B | 10.60% |
| 1998-12-31 | $18.28B | 9.48% |
| 1997-12-31 | $16.70B | 10.86% |
| 1996-12-31 | $15.06B | 9.43% |
| 1995-12-31 | $13.77B | 14.88% |
| 1994-12-31 | $11.98B | 5.00% |
| 1993-12-31 | $11.41B | - |
Bristol-Myers Squibb generated $45.01B in revenue during NA 2023, up -2.50% compared to the previous quarter, and up 199.49% compared to the same period a year ago.
Bristol-Myers Squibb Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $12.20B | 2.83% |
| 2024-03-31 | $11.87B | 3.38% |
| 2023-12-31 | $11.48B | 4.66% |
| 2023-09-30 | $10.97B | -2.32% |
| 2023-06-30 | $11.23B | -0.98% |
| 2023-03-31 | $11.34B | -0.60% |
| 2022-12-31 | $11.41B | 1.68% |
| 2022-09-30 | $11.22B | -5.63% |
| 2022-06-30 | $11.89B | 2.05% |
| 2022-03-31 | $11.65B | -2.81% |
| 2021-12-31 | $11.98B | 3.11% |
| 2021-09-30 | $11.62B | -0.68% |
| 2021-06-30 | $11.70B | 5.69% |
| 2021-03-31 | $11.07B | 0.05% |
| 2020-12-31 | $11.07B | 5.01% |
| 2020-09-30 | $10.54B | 4.06% |
| 2020-06-30 | $10.13B | -6.05% |
| 2020-03-31 | $10.78B | 35.70% |
| 2019-12-31 | $7.95B | 32.26% |
| 2019-09-30 | $6.01B | -4.24% |
| 2019-06-30 | $6.27B | 5.96% |
| 2019-03-31 | $5.92B | -0.89% |
| 2018-12-31 | $5.97B | 4.96% |
| 2018-09-30 | $5.69B | -0.23% |
| 2018-06-30 | $5.70B | 9.84% |
| 2018-03-31 | $5.19B | -4.70% |
| 2017-12-31 | $5.45B | 3.71% |
| 2017-09-30 | $5.25B | 2.14% |
| 2017-06-30 | $5.14B | 4.36% |
| 2017-03-31 | $4.93B | -5.99% |
| 2016-12-31 | $5.24B | 6.52% |
| 2016-09-30 | $4.92B | 1.05% |
| 2016-06-30 | $4.87B | 10.93% |
| 2016-03-31 | $4.39B | 2.43% |
| 2015-12-31 | $4.29B | 5.36% |
| 2015-09-30 | $4.07B | -2.26% |
| 2015-06-30 | $4.16B | 3.02% |
| 2015-03-31 | $4.04B | -5.10% |
| 2014-12-31 | $4.26B | 8.59% |
| 2014-09-30 | $3.92B | 0.82% |
| 2014-06-30 | $3.89B | 2.05% |
| 2014-03-31 | $3.81B | -14.19% |
| 2013-12-31 | $4.44B | 9.25% |
| 2013-09-30 | $4.07B | 0.42% |
| 2013-06-30 | $4.05B | 5.66% |
| 2013-03-31 | $3.83B | -8.59% |
| 2012-12-31 | $4.19B | 12.18% |
| 2012-09-30 | $3.74B | -15.91% |
| 2012-06-30 | $4.44B | -15.39% |
| 2012-03-31 | $5.25B | -3.72% |
| 2011-12-31 | $5.45B | 2.04% |
| 2011-09-30 | $5.34B | -1.64% |
| 2011-06-30 | $5.43B | 8.44% |
| 2011-03-31 | $5.01B | -1.96% |
| 2010-12-31 | $5.11B | 6.52% |
| 2010-09-30 | $4.80B | 0.63% |
| 2010-06-30 | $4.77B | -0.81% |
| 2010-03-31 | $4.81B | 64.51% |
| 2009-12-31 | $2.92B | -46.75% |
| 2009-09-30 | $5.49B | 1.91% |
| 2009-06-30 | $5.38B | 7.36% |
| 2009-03-31 | $5.01B | -4.46% |
| 2008-12-31 | $5.25B | -0.10% |
| 2008-09-30 | $5.25B | 0.98% |
| 2008-06-30 | $5.20B | 0.42% |
| 2008-03-31 | $5.18B | 5.86% |
| 2007-12-31 | $4.89B | - |
Bristol-Myers Squibb generated $12.20B in revenue during Q2 2024, up 2.83% compared to the previous quarter, and up 107.62% compared to the same period a year ago.
Bristol-Myers Squibb Revenue Breakdown
Bristol-Myers Squibb Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Yervoy | $2.13B | $2.03B | $1.68B | $1.49B | $1.33B |
| Abecma | $388.00M | $164.00M | - | - | - |
| Abraxane | $811.00M | $1.18B | $1.25B | $166.00M | - |
| Breyanzi | $182.00M | $87.00M | - | - | - |
| Eliquis | $11.79B | $10.76B | $9.17B | $7.93B | $6.44B |
| Empliciti | $296.00M | $334.00M | $381.00M | $357.00M | $247.00M |
| Inrebic | $85.00M | $74.00M | $55.00M | $5.00M | - |
| Mature Products And All Other | $1.75B | $1.90B | $1.31B | $1.67B | $1.63B |
| Onureg | $124.00M | $73.00M | $17.00M | - | - |
| Opdivo | $8.25B | $7.52B | $6.99B | $7.20B | $6.74B |
| Opdualag | $252.00M | - | - | - | - |
| Orencia | $3.46B | $3.31B | $3.16B | $2.98B | $2.71B |
| Pomalyst/Imnovid | $3.50B | $3.33B | $3.07B | $322.00M | - |
| Reblozyl | $717.00M | $551.00M | $274.00M | - | - |
| Sotyktu | $8.00M | - | - | - | - |
| Camzyos | $24.00M | - | - | - | - |
| Sprycel | $2.17B | $2.12B | $2.14B | $2.11B | $2.00B |
| Revlimid | $9.98B | $12.82B | $12.11B | $1.30B | - |
| Zeposia | $250.00M | $134.00M | $12.00M | - | - |
| Baraclude | - | - | $447.00M | $555.00M | $744.00M |
| Vidaza | - | - | $455.00M | $58.00M | - |
| Hepatitis C Portfolio | - | - | - | - | $17.00M |
| Sustiva Franchise | - | - | - | - | $283.00M |
| Reyataz | - | - | - | - | $427.00M |
Bristol-Myers Squibb's latest annual revenue breakdown by segment (product or service), as of Dec 22: Eliquis (25.54%), Revlimid (21.62%), Opdivo (17.87%), Pomalyst/Imnovid (7.58%), Orencia (7.50%), Sprycel (4.69%), Yervoy (4.62%), Mature Products And All Other (3.79%), Abraxane (1.76%), Reblozyl (1.55%), Abecma (0.84%), Empliciti (0.64%), Opdualag (0.55%), Zeposia (0.54%), Breyanzi (0.39%), Onureg (0.27%), Inrebic (0.18%), Camzyos (0.05%), and Sotyktu (0.02%).
Quarterly Revenue by Product
| Product/Service | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Camzyos | $46.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Sotyktu | $25.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Yervoy | $585.00M | $508.00M | $568.00M | $523.00M | $525.00M | $515.00M | $545.00M | $515.00M | $510.00M | $456.00M | $471.00M | $446.00M | $369.00M | $396.00M | $385.00M | $353.00M | $367.00M | $384.00M | $382.00M | $315.00M |
| Zeposia | $100.00M | $78.00M | $79.00M | $69.00M | $66.00M | $36.00M | $48.00M | $40.00M | $28.00M | $18.00M | $9.00M | $2.00M | $1.00M | - | - | - | - | - | - | - |
| Abecma | $132.00M | $147.00M | $125.00M | $107.00M | $89.00M | $67.00M | $69.00M | $71.00M | $24.00M | - | - | - | - | - | - | - | - | - | - | - |
| Abraxane | $258.00M | $239.00M | $179.00M | $177.00M | $241.00M | $214.00M | $305.00M | $266.00M | $296.00M | $314.00M | $297.00M | $342.00M | $308.00M | $300.00M | - | - | - | - | - | - |
| Eliquis | $3.20B | $3.42B | $2.69B | $2.65B | $3.23B | $3.21B | $2.67B | $2.41B | $2.79B | $2.89B | $2.27B | $2.10B | $2.16B | $2.64B | $2.03B | $1.93B | $2.04B | $1.93B | $1.58B | $1.65B |
| Inrebic | $27.00M | $25.00M | $23.00M | $21.00M | $23.00M | $18.00M | $20.00M | $22.00M | $16.00M | $16.00M | $15.00M | $13.00M | $15.00M | $12.00M | - | - | - | - | - | - |
| Mature and Other Brands | $472.00M | $467.00M | $441.00M | $435.00M | $462.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Onureg | $44.00M | $34.00M | $37.00M | $32.00M | $32.00M | $23.00M | $25.00M | $21.00M | $12.00M | $15.00M | $14.00M | $3.00M | - | - | - | - | - | - | - | - |
| Opdivo | $2.15B | $2.20B | $2.22B | $2.05B | $2.06B | $1.92B | $1.99B | $1.91B | $1.91B | $1.72B | $1.79B | $1.78B | $1.65B | $1.77B | $1.76B | $1.82B | $1.82B | $1.80B | $1.79B | $1.63B |
| Breyanzi | $100.00M | $71.00M | $55.00M | $44.00M | $39.00M | $44.00M | $40.00M | $30.00M | $17.00M | - | - | - | - | - | - | - | - | - | - | - |
| Opdualag | $154.00M | $117.00M | $104.00M | $84.00M | $58.00M | $6.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Orencia | $927.00M | $764.00M | $913.00M | $883.00M | $876.00M | $792.00M | $864.00M | $870.00M | $814.00M | $758.00M | $867.00M | $826.00M | $750.00M | $714.00M | $792.00M | $767.00M | $778.00M | $640.00M | $675.00M | $711.00M |
| Pomalyst/Imnovid | $847.00M | $832.00M | $877.00M | $886.00M | $908.00M | $826.00M | $854.00M | $851.00M | $854.00M | $773.00M | $835.00M | $777.00M | $745.00M | $713.00M | - | - | - | - | - | - |
| Reblozyl | $234.00M | $206.00M | $199.00M | $190.00M | $172.00M | $156.00M | $151.00M | $160.00M | $128.00M | $112.00M | $115.00M | $96.00M | $55.00M | $8.00M | - | - | - | - | - | - |
| Revlimid | $1.47B | $1.75B | $2.26B | $2.42B | $2.50B | $2.80B | $3.33B | $3.35B | $3.20B | $2.94B | $3.28B | $3.03B | $2.88B | $2.92B | - | - | - | - | - | - |
| Sprycel | $458.00M | $429.00M | $578.00M | $560.00M | $544.00M | $483.00M | $555.00M | $551.00M | $541.00M | $470.00M | $564.00M | $544.00M | $511.00M | $521.00M | $549.00M | $558.00M | $544.00M | $459.00M | $491.00M | $535.00M |
| Empliciti | - | - | $71.00M | $73.00M | $77.00M | $75.00M | $81.00M | $82.00M | $86.00M | $85.00M | $91.00M | $96.00M | $97.00M | $97.00M | $94.00M | $89.00M | $91.00M | $83.00M | $59.00M | $64.00M |
| Mature Products And All Other | - | - | - | - | - | - | $903.00M | $339.00M | $319.00M | $339.00M | $279.00M | $287.00M | $331.00M | $418.00M | $356.00M | $350.00M | $481.00M | $487.00M | - | - |
| Vidaza | - | - | - | - | - | - | - | $36.00M | $45.00M | $54.00M | $65.00M | $106.00M | $126.00M | $158.00M | - | - | - | - | - | - |
| Baraclude | - | - | - | - | - | - | - | $105.00M | $109.00M | $113.00M | $104.00M | $100.00M | $121.00M | $122.00M | $122.00M | $145.00M | $147.00M | $141.00M | $175.00M | $179.00M |
| Sustiva Franchise | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $72.00M | $73.00M |
| Reyataz | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $87.00M | $117.00M |
| Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $382.00M | $421.00M |
| Hepatitis C Portfolio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.00M | $12.00M |
Bristol-Myers Squibb's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Eliquis (28.54%), Opdivo (19.11%), Revlimid (13.08%), Orencia (8.26%), Pomalyst/Imnovid (7.54%), Yervoy (5.21%), Mature and Other Brands (4.20%), Sprycel (4.08%), Abraxane (2.30%), Reblozyl (2.08%), Opdualag (1.37%), Abecma (1.18%), Zeposia (0.89%), Breyanzi (0.89%), Camzyos (0.41%), Onureg (0.39%), Inrebic (0.24%), and Sotyktu (0.22%).
Bristol-Myers Squibb Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| European Union | $13.50B | $10.69B | $9.85B | $6.27B | $5.66B |
| Other Region | $834.00M | $852.00M | $631.00M | $524.00M | $584.00M |
| UNITED STATES | $31.83B | $29.21B | $26.58B | $15.34B | $12.59B |
| Europe | $13.50B | - | - | - | - |
| Rest Of World | - | $5.63B | $5.46B | $4.01B | $3.73B |
Bristol-Myers Squibb's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (53.35%), European Union (22.62%), Europe (22.62%), and Other Region (1.40%).
Quarterly Revenue by Country
| Country | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $7.89B | $8.03B | $7.92B | $7.94B | $8.27B | $7.69B | $7.52B | $7.30B | $7.39B | $7.01B | $6.78B | $6.54B | $6.49B | $6.77B | $4.75B | $3.47B | $3.67B | $3.45B | $3.23B | $3.23B |
| Rest Of World | $3.16B | $1.31B | $1.46B | $1.39B | $1.44B | $1.35B | $1.43B | $1.36B | $1.33B | $1.33B | $1.18B | $976.00M | $988.00M | $874.00M | $932.00M | $923.00M | - | - | - | - |
| Other Region | $175.00M | $155.00M | $200.00M | $215.00M | $192.00M | $227.00M | $221.00M | $276.00M | $191.00M | $164.00M | $162.00M | $184.00M | $172.00M | $113.00M | $166.00M | $114.00M | $127.00M | $117.00M | - | - |
| Europe | - | - | - | - | - | $2.41B | $2.66B | $2.69B | $1.36B | $1.41B | - | - | - | - | - | - | - | - | - | - |
| European Union | - | - | - | - | - | - | - | - | - | $2.55B | $2.70B | $2.45B | $2.14B | $2.57B | $1.85B | $1.45B | $1.49B | $1.48B | - | - |
| Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $159.00M | $143.00M |
Bristol-Myers Squibb's latest quarterly revenue breakdown by geography, as of Jun 23: UNITED STATES (70.29%), Rest Of World (28.15%), and Other Region (1.56%).
Bristol-Myers Squibb Peer Comparison by Revenue
BMY Revenue FAQ
What is Bristol-Myers Squibb’s yearly revenue?
Bristol-Myers Squibb's yearly revenue for 2023 was $45.01B, representing a decrease of -2.50% compared to 2022. The company's yearly revenue for 2022 was $46.16B, representing a decrease of -0.49% compared to 2021. BMY's yearly revenue for 2021 was $46.38B, representing an increase of 9.09% compared to 2020.
What is Bristol-Myers Squibb’s quarterly revenue?
Bristol-Myers Squibb's quarterly revenue for Q2 2024 was $12.2B, a 2.83% increase from the previous quarter (Q1 2024), and a 8.69% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $11.86B, a 3.38% increase from the previous quarter (Q4 2023), and a 4.66% increase year-over-year (Q1 2023). BMY's quarterly revenue for Q4 2023 was $11.48B, a 4.66% increase from the previous quarter (Q3 2023), and a 0.62% increase year-over-year (Q4 2022).
What is Bristol-Myers Squibb’s revenue growth rate?
Bristol-Myers Squibb's revenue growth rate for the last 3 years (2021-2023) was -2.97%, and for the last 5 years (2019-2023) was 72.14%.
What are Bristol-Myers Squibb’s revenue streams?
Bristol-Myers Squibb's revenue streams in c 22 are Yervoy, Abecma, Abraxane, Breyanzi, Eliquis, Empliciti, Inrebic, Mature Products And All Other, Onureg, Opdivo, Opdualag, Orencia, Pomalyst/Imnovid, Reblozyl, Sotyktu, Camzyos, Sprycel, Revlimid, and Zeposia. Yervoy generated $2.13B in revenue, accounting 4.62% of the company's total revenue, up 5.18% year-over-year. Abecma generated $388M in revenue, accounting 0.84% of the company's total revenue, up 136.59% year-over-year. Abraxane generated $811M in revenue, accounting 1.76% of the company's total revenue, down -31.33% year-over-year. Breyanzi generated $182M in revenue, accounting 0.39% of the company's total revenue, up 109.20% year-over-year. Eliquis generated $11.79B in revenue, accounting 25.54% of the company's total revenue, up 9.54% year-over-year. Empliciti generated $296M in revenue, accounting 0.64% of the company's total revenue, down -11.38% year-over-year. Inrebic generated $85M in revenue, accounting 0.18% of the company's total revenue, up 14.86% year-over-year. Mature Products And All Other generated $1.75B in revenue, accounting 3.79% of the company's total revenue, down -7.95% year-over-year. Onureg generated $124M in revenue, accounting 0.27% of the company's total revenue, up 69.86% year-over-year. Opdivo generated $8.25B in revenue, accounting 17.87% of the company's total revenue, up 9.65% year-over-year. Opdualag generated $252M in revenue, accounting 0.55% of the company's total revenue Orencia generated $3.46B in revenue, accounting 7.50% of the company's total revenue, up 4.78% year-over-year. Pomalyst/Imnovid generated $3.5B in revenue, accounting 7.58% of the company's total revenue, up 4.95% year-over-year. Reblozyl generated $717M in revenue, accounting 1.55% of the company's total revenue, up 30.13% year-over-year. Sotyktu generated $8M in revenue, accounting 0.02% of the company's total revenue Camzyos generated $24M in revenue, accounting 0.05% of the company's total revenue Sprycel generated $2.16B in revenue, accounting 4.69% of the company's total revenue, up 2.27% year-over-year. Revlimid generated $9.98B in revenue, accounting 21.62% of the company's total revenue, down -22.17% year-over-year. Zeposia generated $250M in revenue, accounting 0.54% of the company's total revenue, up 86.57% year-over-year.
What is Bristol-Myers Squibb’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Bristol-Myers Squibb was Eliquis. This segment made a revenue of $11.79B, representing 25.54% of the company's total revenue.